Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsColorado, Georgia
Drug(s) in Trial Other Drug Names Main Known Action
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT02091141IIaAdvanced solid tumors with ALK mutations or high TMBMy Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsView DrugsArizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AlectinibALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802ALK kinase inhibitor
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
NCT02584478IIaRecurrent ovarian cancerA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)View DrugsCalifornia, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AnlotinibAL3818VEGFR2/3 kinase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02419417IIaPlatinum resistant or refractory ovarian cancer with BRCA1/2 mutationsA Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic MalignanciesView DrugsCalifornia, Colorado, Oregon, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986158BET inhibitor BMS-986158BET inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02502266II/IIIPlatinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancerA Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)View DrugsAlabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02485990IIPlatinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)View DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02568267IIAdvanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangementsAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsView DrugsArizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101ALK, TRK, ROS1 kinase inhibitor
NCT01953926IIAdvanced solid tumors with activating HER2 mutationsAn Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.View DrugsArizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NeratinibHKI-272, PD272EGFR, HER2, HER4 kinase inhibitor
NCT02203513IIRecurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancerA Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitor
NCT02312245IIPlatinum resistant or refractory ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT01037790IIAdvanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterationsPhase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PalbociclibIbrance, PD0332991, PD-0332991CDK4/6 inhibitor
NCT02272998IIAdvanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterationsPhase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)View DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
Ponatinibmultitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534Multi-targeted kinase inhibitor
NCT02079740IIAdvanced solid tumors with KRAS or NRAS mutations (in expansion)An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
NavitoclaxBcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263Bcl-2, Bcl-XL, and Bcl-w inhibitor
TrametinibTMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, MekinistMEK1/2 inhibitor
NCT01827384IIAdvanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsView DrugsColorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
EverolimusZortress, RAD001, Certican, AfinitormTOR inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
TrametinibTMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, MekinistMEK1/2 inhibitor
VeliparibABT-888PARP inhibitor
NCT02554812IIAdvanced solid tumors (in ovarian expansion)A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced MalignanciesView DrugsCalifornia, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
PD-0360324anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324CSF1R antagonist and tumor-associated macrophage inhibitor
PF-04518600anti-OX40 antibody PF-04518600Stimulates OX40 to increase T cell activation and immune response
NCT02832167IIAdvanced solid tumorsAn Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic MalignanciesView DrugsArizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02693535IIOvarian Expansion for BRCA MUT1/2 or CDKN2A loss or mutation or Advanced solid tumors with molecular alterations in ALK, ROS1, MET, CDK4, CDK6, CSF1R, PDGFR, VEGFR, mTOR, TSC, ERBB2, BRAFV600E/D/K/R, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, ATM, POLD, POLE, high TMB, MSI high)Targeted Agent and Profiling Utilization Registry (TAPUR) StudyView DrugsAlabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
CobimetinibCotellic, GDC-0973, XL518MEK1 inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
DasatinibBMS-354825, SprycelSRC and bcr-abl kinase inhibitor
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PalbociclibIbrance, PD0332991, PD-0332991CDK4/6 inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitor
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TemsirolimusCCI-779, ToriselmTOR inhibitor
TrastuzumabHER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, HerceptinHER2 antagonist
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitor
NCT02465060IIAdvanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2Molecular Analysis for Therapy Choice (MATCH)View DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitor
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitor
LarotrectinibTrk inhibitor LOXO-101Pan-Trk kinase inhibitor
OsimertinibTagrisso, AZD9291, EGFR inhibitor AZD9291, MereletinibEGFR kinase inhibitor
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
SapanisertibTAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128TORC1/2 kinase inhibitor
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TrametinibTMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, MekinistMEK1/2 inhibitor
TrastuzumabHER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, HerceptinHER2 antagonist
VismodegibHedgehog antagonist GDC-0449, Erivedge, GDC-0449Smoothened antagonist
NCT02628067IIAdvanced solid tumors with high MSIA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)View DrugsCalifornia, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02576444IIAdvanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutationsA Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid TumorsView DrugsConnecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
CeralasertibAZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
methoxyamineTRC102Base excision repair inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysis
NCT01697527IIAdvanced NY-ESO-1+ solid tumorsAdoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1
NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccineImmune response against cancer expressing NY-ESO-1
NCT02834013IIAdvanced ovarian germ cell, mucinous, squamous cell, or adenocarcinomaDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsView DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02873975IIAdvanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutationsA Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair DeficiencyView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitor
NCT02900560IIPlatinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsCalifornia, Maryland, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
Oral AzacitidineCC-486DNA methylation inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02843165IIAdvanced solid tumors with lesion treatable with radiotherapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03026062IIPlatinum resistant or refractory ovarian cancerRandomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03093155IIPlatinum resistant, refractory or persistent ovarian cancerA Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancersView DrugsConnecticut, Maryland
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
IxabepiloneAzaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, IxempraMicrotubule stabilizer/mitotic inhibitor
NCT02587598IIAdvanced solid tumors (in expansion)A Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesView DrugsArizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Azacytidineazacitidine, Vidaza, Mylosar, 5-AZCDNA methylation inhibitor
INCB053914pan-PIM inhibitor INCB053914PIM1, 2, 3 inhibitor
NCT02920996IIAdvanced solid tumors with NTRK1-3 rearrangementsA Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK RearrangementsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Merestinibc-Met inhibitor LY2801653, LY2801653Multi-targeted RTK inhibitor
NCT03113487IIPlatinum resistant ovarian cancerP53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
p53MVAModified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53Immune response against p53 tumor antigen
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03212274IIAdvanced solid tumors with IDH1 or IDH2 mutationsA Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid TumorsView DrugsCalifornia, Connecticut, District of Columbia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03253679IIAdvanced solid tumors with CCNE1 AMPA Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 AmplificationView DrugsCalifornia, Colorado, District of Columbia, Florida, Kentucky, New York, North Carolina, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
NCT03274661IIAdvanced solid tumorsEvaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair DeficiencyView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03284385IIAdvanced solid tumors with SETD2 deficiencyA Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesView DrugsCalifornia, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
NCT03300843IIAdvanced solid tumors (with resectable tumor)A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Peptide loaded dendritic cell vaccineAnti-tumor immune response
NCT03310879IIAdvanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplificationsA Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6View DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
NCT03348631IIRecurrent or persistent endometrioid/clear cell ovarian cancerA Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial AdenocarcinomaView DrugsAlaska, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Virginia, Washington, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
Tazemetostathistone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438EZH2 histone methyltransferase inhibitor
NCT03355976IIRecurrent clear cell ovarian cancerBrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasView DrugsRhode Island
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03147976IIAdvanced solid tumors with MET over-expression or mutationA Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) MutationsView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AMG 337c-Met kinase inhibitor
NCT03395080IIPlatinum resistant or refractory ovarian cancerA Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian CancerView DrugsAlabama, Arizona, Florida, Illinois, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
DKN-01DKK1-neutralizing monoclonal antibody DKN-01Dickkopf-1 (DKK1) antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityView DrugsNew Jersey
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT01876511IIAdvanced solid tumors with positive MSI or tumors with negative MSI and high TMBPhase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) TumorsView DrugsCalifornia, Maryland, New York, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsView DrugsFlorida, Michigan, New York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03565991IIAdvanced solid tumors with BRCA1/2 or ATM mutationsA Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant TumorsView DrugsCalifornia, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT03579316IIRecurrent ovarian cancer (PD on or after prior PARP inhibitor)A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionView DrugsMassachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune response
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerView DrugsCalifornia, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03668119IIAdvanced solid tumors with high TMBA Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)View DrugsCalifornia, Colorado, Illinois, Minnesota, New York, North Carolina, Oregon, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03587311IIPlatinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancerA Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerView DrugsMissouri, Ohio
Drug(s) in Trial Other Drug Names Main Known Action
Anetumab ravtansineBAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343ADC: anti-mesothelin + microtubule destabilizer (DM4)
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03682289IIRecurrent ovarian cancerPhase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CeralasertibAZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03693014IIAdvanced solid tumors with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03718091IIAdvanced solid cancer with ATM truncation mutations or other HR gene mutationsA Phase II Study of M6620 (VX-970) in Selected Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
NCT03673124IILow grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
LetrozoleFemaraAromatase inhibitor
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitor
NCT03461952IIAdvanced solid tumors with POLE and/or POLD1 mutationsA Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03776812IIPlatinum resistant or refractory ovarian cancerA Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsArizona, Illinois
Drug(s) in Trial Other Drug Names Main Known Action
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
RelacorilantCORT125134GR antagonist
NCT03834220IIAdvanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusionA Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3View DrugsArizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Debiopharm 1347CH5183284, FF284, FGFR Inhibitor Debio 1347FGFR1-3 inhibitor
NCT03836352IIRecurrent ovarian cancer (with tumor lesions < 5 cm)A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.View DrugsNew York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03797326IIAdvanced solid tumorsA Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)View DrugsCalifornia, Colorado, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
LenvatinibLenvima, ER-203492-00, E7080VEGFR1-3 kinase inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
BrigatinibAP26113ALK and EGFR kinase inhibitor
NCT03697304IIAdvanced solid tumors with prior PD-1/PD-L1 targeted treatmentAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 754111Blocks LAG-3 inhibition of T cells
NCT02819843IIAdvanced solid tumors - intratumoral injectionA Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
Talimogene LaherparepvecGM-CSF-encoding oncolytic herpes simplex virus, T-VECInduces immune response and tumor cell lysis
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
Onapristone ERextended-release onapristonePR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT03935893IIAdvanced solid tumorsA Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid CancersView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
Autologous TILsAnti-tumor immune response
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsView DrugsKentucky
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02710253IIAdvanced solid tumors with progression on systemic immunotherapyPhase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
NCT03449108IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
LN-145autologous tumor infiltrating lymphocytes LN-145, autologous TILs LN-145Anti-tumor immune response
NCT03616834IIAdvanced solid tumors with high MSI on checkpoint inhibitor treatment without evidence of complete or partial responseTomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor AloneView DrugsArizona, California, Georgia, Idaho, Indiana, Maryland, Michigan, Ohio, Oregon, South Carolina, South Dakota, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
TomivosertibeFT508MNK1/2 inhibitor
NCT03861403Ib/IIaAdvanced solid tumors (inc ovarian expansion)A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsView DrugsFlorida, Indiana
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
TRX518anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518GITR (glucocorticoid-induced TNFR) agonist
NCT03684785Ib/IIAdvanced solid tumorsA Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid TumorsView DrugsCalifornia, Florida, Iowa, Massachusetts, Ohio
Drug(s) in Trial Other Drug Names Main Known Action
AST-008TLR9 agonist AST-008TLR agonist and immune cell stimulator
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03684811Ib/IIAdvanced solid tumors with IDH1 mutationsA Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 MutationView DrugsCalifornia, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey, New York, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action
FT-2102mutated IDH1 inhibitor
NCT03601897Ib/IIAdvanced solid tumorsAn Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsView DrugsAlabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitor
NCT02759588Ib/IIPlatinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)View DrugsCalifornia, Florida
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
GL-ONC1light-emitting oncolytic vaccinia virus GL-ONC1Membrane disrupter
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02785250Ib/IIRecurrent ovarian cancerA Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian CancerView DrugsCalifornia, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
NCT02606305Ib/IIAdvanced FRalpha+ ovarian cancerA Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerView DrugsAlabama, California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
NCT02323191IbAdvanced solid tumors (inc ovarian expansion)Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
EmactuzumabRO5509554, RG7155CSF1R antagonist and tumor-associated macrophage inhibitor
NCT02551185IbAdvanced solid tumorsA Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
ACY-241HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241HDAC inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02419495IbAdvanced solid tumors (in expansion)Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy Agents in Patients With Advanced MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
EribulinB1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analogTubulin polymerization inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
SelinexorKPT-330, CRM1 nuclear export inhibitor KPT-330, selective inhibitor of nuclear export KPT-330Selective inhibition of nuclear export (SINE)
NCT03113188IbAdvanced solid tumorsPhase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory TumorsView DrugsArizona, Louisiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action
CBP501G2 checkpoint inhibitor CBP501G2 checkpoint inhibitor
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03239145IbAdvanced solid tumors (inc ovarian expansion)Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
TrebananibAMG 386Angiopoietin 1/2 antagonist
NCT03099174IbAdvanced solid tumorsAn Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.View DrugsCalifornia, Connecticut, Florida, Minnesota, Nevada, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
XentuzumabBI-836845IGF-1/2 antagonist
NCT02994953IbAdvanced solid tumorsA Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonist
NCT03611868IbAdvanced solid tumorsA Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
APG-115MDM2-p53 inhibitor APG-115, p53-HDM2 protein-protein interaction inhibitor APG-115MDM2 inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03621982IbAdvanced solid tumors (inc expansion)A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid TumorsView DrugsCalifornia, Connecticut, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Camidanlumab Tesirineanti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301DNA damaging agent
NCT03650348IbAdvanced HER2+ solid tumors (inc expansion)A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsView DrugsCalifornia, Louisiana, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2
NCT03586661IbRecurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2-wild type)(inc expansion)A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsView DrugsCalifornia, Connecticut, Florida, Illinois, New Jersey, New York, North Carolina, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO1 to stimulate immune response
INCB050465PI3K-delta inhibitor INCB050465PI3K delta inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT02761694IbAdvanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion)A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN MutationsView DrugsOklahoma, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
ARQ 751pan-AKT inhibitor ARQ 751Akt inhibitor
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03558139IbPlatinum resistant or refractory ovarian cancer (inc expansion)A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum ChemotherapyView DrugsIllinois, Michigan, Oklahoma, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
Hu5F9-G4anti-CD47 monoclonal antibody Hu5F9-G4Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03260322IbAdvanced solid tumorsA Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsView DrugsArizona, California, Florida, Iowa, Kansas, Michigan, New York, Pennsylvania, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
ASP8374PTZ-201Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03236935IbAdvanced solid tumors with high MSI or dMMRPhase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
L-NMMApan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginineNOS inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03307785IbAdvanced solid tumorsPhase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerView DrugsArizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TSR-022Blocks TIM-3 inhibition of T cells
TSR-042anti-PD-1 monoclonal antibody TSR-042, ANB011, DostarlimabBlocks PD-L1/2 inhibition of T cells
NCT03168061IbAdvanced solid tumorsA Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaView DrugsCalifornia, Indiana, Missouri, Nevada, New York, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action
NC-6300epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912Topoisomerase II inhibitor
NCT03833427IbAdvanced solid tumorsA Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors.View DrugsCalifornia, Michigan, New Jersey, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
SelumetinibAZD6244, ARRY-142886MEK inhibitor
NCT03875313IbAdvanced solid tumorsA Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CB-839glutaminase inhibitor CB-839Glutaminase inhibitor
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT03449381Ia/IbAdvanced solid tumors (inc expansion)A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid TumorsView DrugsConnecticut, Florida, New York, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BI 907828MDM2 inhibitor
NCT03514121Ia/IbAdvanced solid tumors (in ovarian expansion)A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid TumorsView DrugsArizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
FPA150anti-B7-H4 monoclonal antibody FPA150blocks B7-H4 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03363776I/IIaAdvanced solid tumorsPhase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial TumorsView DrugsArizona, California, Massachusetts, New York, South Dakota
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986277Undisclosed mechanism
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03110107I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsMassachusetts, New Jersey, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986218Blocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02650986I/IIaAdvanced solid tumors (in expansion)A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced MalignanciesView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1
TGFbeta DNRII-transduced Autologous Tumor Infiltrating LymphocytesTGFbeta Dominant Negative Receptor II transduced TILSTGFbeta ligand trap
NCT02913313I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsNew Jersey, New York, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986207anti-TIGIT monoclonal antibody BMS-986207Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02754141I/IIaAdvanced solid tumorsA Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid TumorsView DrugsMaryland, Massachusetts, New York, P